News

Merck, known as MSD outside the United States and Canada, announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for…
Read More...

Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies,…
Read More...

Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted Priority Review for finerenone, an investigational drug for…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the…
Read More...

AvantGen, Inc., a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation,…
Read More...

BeiGene, Ltd. a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced a collaboration and license agreement with…
Read More...

Rocket Pharmaceuticals, Inc. a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the Company’s…
Read More...

Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have…
Read More...

GSK and Medicines for Malaria Venture (MMV) announced that the Australian Therapeutic Goods Administration (TGA) accepted the submission of a Category 1 application to extend the…
Read More...

Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug…
Read More...

Celularity Inc. and GX Acquisition Corp announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity. Upon the…
Read More...

Affinivax, Inc. a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced…
Read More...

Teva Pharmaceuticals Industries Ltd. and MedinCell announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase…
Read More...

Pfizer Inc. announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate…
Read More...

BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK),…
Read More...

Bayer has signed a collaboration and services agreement with CureVac N.V. a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic…
Read More...

Merck, a leading science and technology company, today announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization…
Read More...

ImaginAb Inc. announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer…
Read More...

Almirall, S.A. a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next-generation gene therapy company founded by Columbus Venture Partners, have announced…
Read More...

AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, announced that the first patients with COVID-19 infection and sepsis-associated…
Read More...